Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy
Search Results
CLO23-046: Pooled Outcomes of Anti-BRAF Agents in Advanced Stage Colorectal Cancer
Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha
Vemurafenib Treatment of BRAF V600E-Mutated Malignant Peripheral Nerve Sheath Tumor
Henry G. Kaplan
tumors Discuss the potential benefits of vemurafenib in the presence of a BRAF mutation Malignant peripheral nerve sheath tumors (MPNSTs) are uncommon cancers that can demonstrate extremely aggressive behavior. Primary treatment involves surgical
KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010–2013
Mary E. Charlton, Amanda R. Kahl, Alissa A. Greenbaum, Jordan J. Karlitz, Chi Lin, Charles F. Lynch, and Vivien W. Chen
shown that right-sided cancer is associated with older age (≥75 years), female sex, larger tumor size, higher tumor grade, 14 and more frequent mucinous subtypes, 15 as well as microsatellite instability (MSI), 16 , 17 BRAF mutation, 18 , 19 EGFR
Agents Make “Preferred List” in Metastatic Melanoma
John A. Thompson
investigated further. Molecularly Targeted Agents A better understanding of the genetic landscape of advanced melanoma has led to the successful targeting of key mutations, especially BRAF mutations, which appear to be most frequent in younger
BRAF-Targeted Therapy in the Treatment of BRAF-Mutant High-Grade Gliomas in Adults
Tanner M. Johanns, George Ansstas, and Sonika Dahiya
for these agents in primary CNS disease, and raise several important clinical considerations. Incidence Several large retrospective studies have attempted to estimate the frequency of BRAF mutations in pediatric and adult primary CNS tumors 11
Melanoma, Version 4.2014
Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. Olszanski, Merrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, and Maria Ho
genetic alterations differs among melanoma subtypes. For example, melanoma on nonchronic sun damaged (non-CSD) areas was found to have the highest proportion of BRAF mutations (56%) compared with CSD, acral, and mucosal lesions (6%, 21%, and 3
Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer
Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris
upper lobe (B) compared with prior CT (A). ATC has been shown to harbor RAS, RET, PTEN, PI3KCA, TP53 , and BRAF mutations. 14 – 17 Recently, frameshift insertions in PTEN and TP53 has also been reported in metastatic brain lesions and
BRAF-Mutated Erdheim-Chester Disease: Profound Response to Vemurafenib Visualized With Serial Multimodality Imaging
Javaughn Corey R. Gray, Jongho Kim, Michael Digianvittorio, Nancy K. Feeley, Paul J. Scheel, Stanley S. Siegelman, Elliot K. Fishman, and Steven P. Rowe
histiocyte inflammation, confirming the diagnosis. Due to the presence of histiocytes in biopsy specimens, BRAF mutation analysis was ordered, which was positive for the BRAF V600E mutation. Because of the disease severity, initial treatment with anakinra
Emerging Treatment Options for the Management of Metastatic Colorectal Cancer
Presented by: Dustin A. Deming
all BRAF mutations are equal,” he said. The V600E mutation, which occurs in 8% to 10% of patients with CRC, accounts for 80% of BRAF mutations. Prognosis varies by mutation type: overall survival (OS) is poor for patients with V600E mutations, but
BRAF Inhibition in BRAF V600E-Positive Anaplastic Thyroid Carcinoma
Annette M. Lim, Graham R. Taylor, Andrew Fellowes, Laird Cameron, Belinda Lee, Rodney J. Hicks, Grant A. McArthur, Christopher Angel, Benjamin Solomon, and Danny Rischin
-year smoking history, the patient had no comorbidities. The patient declined both radical surgery and chemoradiotherapy. A core biopsy was performed to confirm the tumor histology and to determine BRAF mutation status. The thyroid biopsy showed a malignancy
